These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38812276)

  • 21. Surrogacy validation for time-to-event outcomes with illness-death frailty models.
    Roberts EK; Elliott MR; Taylor JMG
    Biom J; 2024 Jan; 66(1):e2200324. PubMed ID: 37776057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES).
    Lassere MN; Johnson KR; Schiff M; Rees D
    BMC Med Res Methodol; 2012 Mar; 12():27. PubMed ID: 22409774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An entropy-based nonparametric test for the validation of surrogate endpoints.
    Miao X; Wang YC; Gangopadhyay A
    Stat Med; 2012 Jun; 31(14):1517-30. PubMed ID: 22344829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonparametric comparison of survival functions based on interval-censored data with unequal censoring.
    Feng Y; Duan R; Sun J
    Stat Med; 2017 May; 36(12):1895-1906. PubMed ID: 28239879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A generalization of Turnbull's estimator for nonparametric estimation of the conditional survival function with interval-censored data.
    Dehghan MH; Duchesne T
    Lifetime Data Anal; 2011 Apr; 17(2):234-55. PubMed ID: 20544280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.
    Conlon AS; Taylor JM; Elliott MR
    Biostatistics; 2014 Apr; 15(2):266-83. PubMed ID: 24285772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonparametric Bayesian covariate-adjusted estimation of the Youden index.
    Inácio de Carvalho V; de Carvalho M; Branscum AJ
    Biometrics; 2017 Dec; 73(4):1279-1288. PubMed ID: 28378510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can earlier biomarker measurements explain a treatment effect on diabetes incidence? A robust comparison of five surrogate markers.
    Parast L; Tian L; Cai T; Palaniappan LP
    BMJ Open Diabetes Res Care; 2023 Oct; 11(5):. PubMed ID: 37907279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On assessing surrogacy in a single trial setting using a semicompeting risks paradigm.
    Ghosh D
    Biometrics; 2009 Jun; 65(2):521-9. PubMed ID: 18759839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonparametric estimation of time-dependent ROC curves conditional on a continuous covariate.
    Rodríguez-Álvarez MX; Meira-Machado L; Abu-Assi E; Raposeiras-Roubín S
    Stat Med; 2016 Mar; 35(7):1090-102. PubMed ID: 26487068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Interplay between Fasting Glucose, Echocardiography, and Biomarkers: Pathophysiological Considerations and Prognostic Implications.
    Pareek M
    Dan Med J; 2017 Sep; 64(9):. PubMed ID: 28874244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel nonparametric time-dependent precision-recall curve estimator for right-censored survival data.
    Beyene KM; Chen DG; Kifle YG
    Biom J; 2024 Apr; 66(3):e2300135. PubMed ID: 38637327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new proportion measure of the treatment effect captured by candidate surrogate endpoints.
    Kobayashi F; Kuroki M
    Stat Med; 2014 Aug; 33(19):3338-53. PubMed ID: 24782344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generalized log-rank tests for partly interval-censored failure time data.
    Zhao X; Zhao Q; Sun J; Kim JS
    Biom J; 2008 Jun; 50(3):375-85. PubMed ID: 18435504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surrogacy assessment using principal stratification and a Gaussian copula model.
    Conlon A; Taylor J; Elliott MR
    Stat Methods Med Res; 2017 Feb; 26(1):88-107. PubMed ID: 24947559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal survival time-related cut-point with censored data.
    Liu X; Jin Z
    Stat Med; 2015 Feb; 34(3):515-24. PubMed ID: 25382379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonparametric empirical Bayes biomarker imputation and estimation.
    Barbehenn A; Zhao SD
    Stat Med; 2024 Aug; 43(19):3742-3758. PubMed ID: 38897921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of longitudinal surrogate markers.
    Agniel D; Parast L
    Biometrics; 2021 Jun; 77(2):477-489. PubMed ID: 32506496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doubly robust evaluation of high-dimensional surrogate markers.
    Agniel D; Hejblum BP; Thiébaut R; Parast L
    Biostatistics; 2023 Oct; 24(4):985-999. PubMed ID: 35791753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.